DRRX DURECT Corporation

1.36
+0.06  (+5%)
Previous Close 1.3
Open 1.3
Price To Book 11.33
Market Cap 261,041,438
Shares 191,942,234
Volume 307,710
Short Ratio
Av. Daily Volume 1,448,904

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

FDA Approval announced July 27, 2018.
RBP-7000
Schizophrenia
Phase 2 top-line data due 2H 2019.
DUR-928
Psoriasis
CRL issued February 12, 2014.
Posidur
Post-operative pain relief
CRL Feb 12 2014. New PDUFA date December 27, 2019.
POSIMIR
Post-operative pain relief
Phase 3 to be initiated by ZGNX once partner is found.
Relday
Schizophrenia
Phase 1b initial data due 2H 2019.
DUR-928
Nonalcoholic steatohepatitis (NASH)
Phase 2 preliminary data noted May 8, 2019. Top-line data due 2H 2019.
DUR-928
Alcoholic hepatitis (AH)

Latest News

  1. Edited Transcript of DRRX earnings conference call or presentation 1-Aug-19 8:30pm GMT
  2. DURECT Corporation Announces Second Quarter 2019 Financial Results and Update of Programs
  3. Health Care Digest: Kilroy's Oyster Point mystery, helping researchers ditch spreadsheets — and more
  4. DURECT Corporation to Announce Second Quarter 2019 Financial Results on August 1
  5. Why Durect Corporation Is Soaring Today
  6. DURECT and Gilead Enter into License Agreement for Long-Acting Injectable HIV Investigational Product
  7. DURECT Announces that the FDA Agreed to File the Full Response to the POSIMIR® Complete Response Letter as a Complete Class 2 Resubmission
  8. DRRX: Favorable FDA Decision on POSIMIR Would Likely Mean Significant Upside to Our Model
  9. DURECT Announces Submission to FDA of a Full Response to the POSIMIR® Complete Response Letter
  10. The Daily Biotech Pulse: Decision Day For Regeneron-Sanofi, Vermillion Offering, PDL BioPharma CFO to Depart
  11. DURECT Receives Approval from Nasdaq for Transfer of Listing to Nasdaq Capital Market
  12. DURECT Announces $15 Million Registered Direct Offering
  13. DURECT Announces Completion of the 90 mg Severe Cohort and Dose Escalation Committee Approval to Commence 150 mg Dosing in Patients with Severe Alcoholic Hepatitis (AH) in its Ongoing DUR-928 Phase 2a AH Trial
  14. Edited Transcript of DRRX earnings conference call or presentation 8-May-19 12:30pm GMT
  15. DRRX: Highly Compelling Initial Ph2a DUR-928 Alcoholic Hepatitis Data. Final Data Later This Year Could Be Value Inflection Event
  16. DURECT to Present at the 20th Annual B. Riley FBR Institutional Investor Conference on May 22, 2019
  17. DURECT Corporation Announces Preliminary Data from the Ongoing DUR-928 Alcoholic Hepatitis Phase 2a Trial
  18. The Daily Biotech Pulse: Daiichi's Positive Breast Cancer Trial, Supernus Slumps, Axovant Reverse Split
  19. DURECT Corp. to Host Earnings Call
  20. Durect: 1Q Earnings Snapshot